# Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

> **NCT00733746** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 123 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00733746
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-11
- **Final completion:** 2019-06-15
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00733746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00733746, "Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00733746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*